Abstract
The multidrug resistance proteins (MRPs) MRP1, MRP2, MRP3, MRP5 and P-glycoprotein (P-gp) act in concert with each other to give a net resultant pump function in acute myeloid leukemia (AML). The aim of the present study was to analyze the activity of these proteins, which might be upregulated at relapse as compared with de novo AML due to clonal selection. The mRNA expression and activity of P-gp and the MRPs were determined with RT-PCR and flow cytometry, in conjunction with phenotype, as measured with the monoclonal antibodies CD34, CD38 and CD33, in 30 paired samples of de novo and relapsed AML. P-gp and MRP activity varied strongly between the cases (rhodamine 123 efflux-blocking by PSC833: 5.4 ± 7.7, and carboxyfluorescein efflux-blocking by MK-571: 4.3 ± 6.7, n = 60). P-gp and MRP activity were increased in 23% and 40% of the relapse samples, and decreased in 30% and 20% of the relapse samples, respectively (as defined by a difference of >2 × standard deviation of the assays). Up- or downregulation of mRNA expression was observed for MDR1 (40%), MRP1 (20%), MRP2 (15%), MRP3 (30%), and MRP5 (5%). Phenotyping demonstrated a more mature phenotype in 23% of the relapsed AML cases, and a more immature phenotype in 23% of the relapses, which was independent of the karyotypic changes that were observed in 50% of the studied cases. P-gp and MRP activity correlated with the phenotypic changes, with higher P-gp and MRP activities in less mature cells (r = −0.66, P < 0.001 and r = −0.31, P = 0.02, n = 58). In conclusion, this study shows that P-gp and MRP activity are not consistently upregulated in relapsed AML. However, P-gp and MRP activities were correlated with the maturation stage as defined by immune phenotype, which was observed to be different in 46% of the relapses.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Marie J-P, Zittoun R, Sikic BI . Multidrug resistance (MDR1) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity Blood 1991 78: 586–592
Campos L, Guyotat D, Archimbaud E, Calmard-Oriol P, Tsuruo T, Troncy J, Treille D, Fiere D . Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis Blood 1992 79: 473–476
Guerci A, Merlin HL, Missoun N, Feldmann L, Marchal S, Witz F, Rose C, Guerci O . Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry Blood 1995 85: 2147–2153
Leith CP, Kopecky KJ, Chen IM, Eijdems L, Slovak ML, Mc Connell TS, Head DR, Weick J, Grever MR, Appelbaum FR, Willman CL . Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1 and LRP in acute myeloid leukemia: a southwest Oncology Group Study Blood 1999 94: 1086–1099
Michieli M, Damiani D, Ermacora A, Masolini P, Raspadori D, Visani O, Scheper RJ, Baccarani M . P-glycoprotein, lung resistance-related protein and multidrug resistance associated protein in de novo acute non-lymphocytic leukaemias: biological and clinical implications Br J Haematol 1999 104: 328–335
Legrand O, Perrot J-Y, Simonin G, Baudard M, Marie J-P . JC-1: a very sensitive fluorescent probe to test Pgp activity in adult acute myeloid leukemia Blood 2001 97: 502–508
Simon M, Schindler M . Cell biological mechanisms of multidrug resistance in tumor Proc Natl Acad Sci USA 1994 91: 3497–3504
Licht T, Pastan I, Gottesman MM, Hermann F . The multidrug resistance gene in gene therapy of cancer and hematopoietic disorders Ann Hematol 1996 72: 184–193
Cole SPC, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AMV, Deeley RG . Overexpression of a novel transporter gene in a multidrug resistance human lung cancer cell line Science 1992 258: 1650–1654
Legrand O, Simonin G, Perrot J-Y, Zittoun R, Marie J-P . Pgp and MRP activities using calcein-AM are prognostic factors in adult acute myeloid leukemia patients Blood 1998 91: 4480–4488
Legrand O, Simonin G, Beauchamp-Nicoud A, Zittoun R, Marie J-P . Simultaneous activity of MRP1 and Pgp is correlated with in vitro resistance to daunorubicin and with in vivo resistance in adult acute myeloid leukemia Blood 1999 94: 1046–1056
Van der Kolk DM, de Vries EGE, van Putten WLJ, Verdonck LF, Ossenkoppele GJ, Verhoef EG, Vellenga E . P-gp and MRP activities in relation to treatment outcome in acute myeloid leukemia Clin Cancer Res 2000 6: 3205–3214
Marbeuf-Gueye C, Broxterman HJ, Dubru F, Priebe W, Garnier-Suillerot A . Kinetics of anthracycline efflux from multidrug resistance protein-expressing cancer cells compared with P-glycoprotein-expressing cancer cells Mol Pharmacol 1998 53: 141–147
Loe DW, Almquist KC, Deeley RG, Cole SPC . Multidrug resistance protein (MRP)-mediated transport of leukotriene C4 and chemotherapeutic agents in membrane vesicles. Demonstration of glutathione-dependent vincristine transport J Biol Chem 1996 271: 9675–9682
Renes J, de Vries EGE, Nienhuis EF, Jansen PLM, Müller M . ATP- and glutathione-dependent transport of chemotherapeutic drugs by the multidrug resistance protein MRP1 Br J Pharmacol 1999 126: 681–688
Taniguchi K, Wada M, Kohno K, Nakamura T, Kawabe T, Kawakami M, Kagotani K, Okumura K, Akiyama S, Kuwano M . A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplain-resistant human cancer cell lines with decreased drug accumulation Cancer Res 1996 56: 4124–4129
Kool M, de Haas M, Scheffer GL, Scheper RJ, van Eijk M, Juijn JA, Baas F, Borst P . Analysis of expression of cMOAT (MRP2), MRP3, MRP4 and MRP5, homologs of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines Cancer Res 1997 57: 3537–3547
Kool M, van der Linden M, de Haas M, Baas F, Borst P . Expression of human MRP6, a homologue of the multidrug resistance protein gene MRP1, in tissues and cancer cells Cancer Res 1999 59: 175
Hopper E, Belinsky MG, Zeng H, Tosolini A, Testa JR, Kruh GD . Analysis of the structure and expression pattern of MRP7 (ABCC10), a new member of the MRP subfamily Cancer Lett 2001 162: 181–191
Keppler D, Cui Y, Koning J, Leier I, Nies A . Export pumps for anionic conjugates encoded by MRP genes Adv Enzyme Regul 1999 39: 237–246
Kool M, van der Linden M, de Haas M, Scheffer GL, de Vree ML, Smith AJ, Jansen G, Peters GJ, Ponne N, Scheper RJ, Oude Elferink RPJ, Baas F, Borst P . MRP3, an organic anion transporter able to transport anti-cancer drugs Proc Natl Acad Sci USA 1999 96: 6914–6919
Lee K, Klein-Szanto AJ, Kruh GD . Analysis of the MRP4 drug resistance profile in transfected NIH3T3 cells J Natl Cancer Inst 2000 92: 1934–1940
Schuetz JD, Connelly MC, Sun D, Paibir SG, Flynn PM, Srinivas RV, Kumar A, Fridland A . MRP4: a previously unidentified factor in resistance to nucleoside-based antiviral drugs Nat Med 1999 5: 1048–1051
Wijnholds J, Mol CAAM, van Deemter L, de Haas M, Scheffer GL, Baas F, Beijnen JH, Scheper RJ, Hatse S, De Clerq E, Balzarini J, Borst P . Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs Proc Natl Acad Sci USA 2000 97: 7476–7481
Jedlitschky G, Burchell B, Keppler D . The multidrug resistance protein 5 (MRP5) functions as an ATP-dependent export pump for cyclic nucleotides J Biol Chem 2000 275: 30069–30074
Funke I, Wiesneth M, Platow S, Kubanek B . Palliative cytoreduction in refractory acute leukemia: a retrospective study of 57 adult patients Ann Hematol 2000 79: 132–137
Miyawaki S, Tanimoto M, Kobayashi T, Minami S, Tamura J, Omoto E, Kuriyama K, Hatake K, Saito K, Kanamaru A, Oh H, Ohtake S, Asou N, Sakamaki H, Yamada O, Jinnai I, Tsubaki K, Takeyama K, Hiraoka A, Matsuda S, Takahashi M, Shimazaki C, Adachi K, Kageyama S, Ohno R et al. No beneficial effect from addition of etoposide to daunorubicin, cytarabine, and 6-mercaptopurine in individualized induction therapy of adult acute myeloid leukemia: the JALSG-AML92 study. Japan Adult Leukemia Study Group Int J Hematol 1999 70: 97–104
Coulthard SA, Howell C, Robson J, Hall AG . The relationship between thiopurine methyltransferase activity and genotype in blasts from patients with acute leukemia Blood 1998 92: 2856–2862
Mayer JR, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P, Omura GA, Moore JO, McIntyre OR, Frei E . Third intensive postremission chemotherapy in adults with acute myeloid leukemia New Engl J Med 1994 331: 896–903
Cassileth PA, Lynch E, Hines JD . Varying intensity of postremission therapy in acute myeloid leukemia Blood 1993 79: 1924–1930
Schiller G, Gajewski J, Territo M . Long-term outcome of high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia Blood 1992 80: 2977–2982
Cassileth PA, Harrington DP, Appelbaum FR, Hillard ML, Rowe JM, Paiette E, Willman C, Hurd DD, Bennett JM, Blume KG, Head DR, Wiernik PH . Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission New Engl J Med 1998 339: 1649–1656
Godwin JE, Kopecky KJ, Head DR . A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group Study (9031) Blood 1998 15: 3607–3615
Löwenberg B, Van Putten WLJ, Verdonck LF . Autologous bone marrow transplantation in acute myeloid leukemia in first remission: results of a Dutch prospective study J Clin Oncol 1990 8: 287–294
Burnett AK, Transey P, Watkins R . Transplantation of unpurged autologous bone-marrow in acuate myeloid leukaemia in first remission Lancet 1984 2: 1068–1070
Lyttelton MP, Hart S, Ganeshaguru K, Hoffbrand AV, Mehta AB . Quantitation of multidrug resistant MDR1 transcript in acute myeloid leukaemia by non-isotopic quantitative cDNA polymerase chain reaction Br J Haematol 1994 86: 540–546
Beck J, Handgretinger R, Klingebiel T, Dopfer R, Schaich M, Ehninger G, Niethammer D, Gekeler V . Expression of PKC isozyme and MDR-associated genes in primary and relapsed state AML Leukemia 1996 10: 423–433
Zhou DC, Zittoun R, Marie JP . Expression of multidrug resistance-associated protein (MRP) and multidrug resistance (MDR1) genes in acute myeloid leukemia Leukemia 1995 9: 1661–1665
Schneider E, Cowan KH, Bader H, Toomey S, Schwartz GN, Karp JE, Burke PJ, Kaufmann SH . Increased expression of the multidrug resistance-associated protein gene in relapsed acute leukemia Blood 1995 85: 186–193
Estey E, Keating MJ, Pierce S, Stass S . Change in karyotype between diagnosis and first relapse in acute myelogenous leukemia Leukemia 1995 9: 972–977
Garson OM, Hagemeijer A, Sakurai M, Reeves BR, Swansbury GJ, Williams GJ, Alimena G, Arthur DC, Berger R, de la Chapelle A . Cytogenetic studies of 103 patients with acute myelogenous leukemia in relapse Cancer Genet Cytogenet 1989 40: 187–202
Van der Kolk DM, Vellenga E, van der Veen AY, Noordhoek L, Timmer-Bosscha H, Ossenkoppele GJ, Raymakers RA, Müller M, van den Berg E, de Vries EGE . Deletion of the multidrug resistance protein MRP1 gene in acute myeloid leukemia: the impact on MRP activity Blood 2000 95: 3514–3519
Te Boekhorst PAW, de Leeuw K, Schoester M, Wittebol S, Nooter K, Hagemeyer A, Löwenberg B, Sonneveld P . Predominance of functional multidrug resistance (MDR-1) phenotype in CD34+ acute myeloid leukemia cells Blood 1993 82: 3157–3162
Gralnick HR . Classification of acute leukemia Ann Intern Med 1977 87: 740
Van der Kolk DM, de Vries EGE, Koning JA, van den Berg E, Müller M, Vellenga E . Activity and expression of the multidrug resistance proteins MRP1 and MRP2 in acute myeloid leukemia cells, tumor cell lines and normal hematopoietic CD34+ peripheral blood cells Clin Cancer Res 1998 4: 1727–1736
Jones TR, Zamboni R, Belley M, Champion E, Charette L, Ford-Hutchinson AW, Frenette R, Gauthier J-Y, Leger S, Masson P, McFarlane S, Piechuta H, Rokach J, Williams H, Young RN . Pharmacology of L-660, 711 (MK-571): a novel potent and selective leukotriene D4 receptor antagonist Can J Physiol Pharmacol 1989 67: 17–28
Löwenberg B, Suciu S, Archimbaud E, Haak H, Stryckmans P, de cataldo R, Dekker AW, Berneman ZN, Thyss A, Van der Lelie J, Sonneveld P, Visani G, Fillet G, Hayat M, Hagemeijer A, Solbu G, Zittoun R . Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy—the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch–Belgian Hemato-Oncology Cooperative Hovon Group J Clin Oncol 1998 15: 872–881
Vellenga E, van Putten WLJ, Boogaerts MA, Daenen SMGJ, Verhoef GEG, Hagenbeek A, Jonkhoff AR, Huijgens PC, Verdonck LF, van der Lelie J, Schouten HC, Gmür J, Wijermans P, Gratwohl A, Hess U, Fey MF, Löwenberg B . Peripheral blood stem cell transplantation as an alternative to autologous marrow transplantation in the treatment of acute myeloid leukemia Bone Marrow Transplant 1999 23: 1279–1282
Keppler D, Cui Y, Konig J, Leier I, Nies A . Export pumps for anionic conjugates encoded by MRP genes Adv Enzyme Regul 1999 39: 237–246
Cantz T, Nies AT, Brom M, Hofmann AF, Kepper D . MRP2, a human conjugate export pump, is present and transports fluo 3 into apical vacuole of Hep G2 cells Am J Physiol Gastrointest Liver Physiol 2000 278: G522–G531
Barhoumi R, Bowen JA, Stein LS, Echols J, Burghardt RC . Concurrent analysis of intracellular glutathione content and gap junctional intercellular communication Cytometry 1993 14: 747–756
Kornblau SM, Estey E, Madden T, Tran HT, Zhao S, Consoli U, Snell V, Sanchez-Williams G, Kantarjian H, Keating M, Newman RA, Andreeff M . Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia J Clin Oncol 1997 15: 1796–1802
Advani R, Visani G, Milligan D, Saba H, Tallman M, Rowe JM, Wiernik PH, Ramek J, Dugan K, Lum B, Villena J, Davis E, Paietta E, Litchman M, Covelli A, Sikic B, Greenberg P . Treatment of poor prognosis AML patients using PSC833 (valdospar) plus mitoxantrone, etoposide, and cytarabine (PSC-MEC) Adv Exp Med Biol 1999 457: 47–56
Acknowledgements
This study was supported by a grant of the Foundation of Pediatric Oncology Groningen (SKOG 99–01).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
van der Kolk, D., de Vries, E., Noordhoek, L. et al. Activity and expression of the multidrug resistance proteins P-glycoprotein, MRP1, MRP2, MRP3 and MRP5 in de novo and relapsed acute myeloid leukemia. Leukemia 15, 1544–1553 (2001). https://doi.org/10.1038/sj.leu.2402236
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2402236
Keywords
This article is cited by
-
Homology modelling, vHTS, pharmacophore, molecular docking and molecular dynamics studies for the identification of natural compound-derived inhibitor of MRP3 in acute leukaemia treatment
Chemical Papers (2022)
-
Lung resistance-related protein (LRP) predicts favorable therapeutic outcome in Acute Myeloid Leukemia
Scientific Reports (2019)
-
A novel mechanism governing the transcriptional regulation of ABC transporters in MDR cancer cells
Drug Delivery and Translational Research (2017)
-
MRP3: a molecular target for human glioblastoma multiforme immunotherapy.
BMC Cancer (2010)
-
Multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase/Akt signal transduction network in human acute myelogenous leukemia blasts
Leukemia (2007)